Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

RegSmart Life Science AB

Scientific Solutions

Advanced Microfluidics Flow Analysis Made Easy

Case study with ZEISS Airyscan.

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Carl Zeiss Meditec achieves revenue growth and stable operating profit

Further recovery in order entry compared to prior year.

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...

Medical device quality assurance

Recordings from ZEISS Quality Innovation Days.

Computed tomography in measurement of medical plastic products

Watch the recordings from ZEISS Quality Innovation Summit.

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

Quality assurance for research and development of medical devices

Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

What will be the next big hype after obesity? – An expert panel highlighted their top picks

What will be the next big trend in life science? Everything from Alzheimer’s, Crispr and Omics were highlighted when the issue was debated at this year’s major ...